Retesting HER2 status in axillary node metastases is important potential as a guide to subsequent therapy after pathologic complete eradication of cytologically proven hormone receptor positive and HER2-negative primary breast cancer following neoadjuvant treatment.
Retesting HER2 status in axillary node metastases is important potential as a guide to subsequent therapy after pathologic complete eradication of cytologically proven hormone receptor positive and HER2-negative primary breast cancer following neoadjuvant treatment.
J BUON. 2018 Nov-Dec;23(6):1930
Authors: Altundag K
Abstract
PMID: 30610827 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cytology | HER2 | Hormones | Neoadjuvant Therapy